medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2021, Número 3

<< Anterior Siguiente >>

Rev Mex Urol 2021; 81 (3)


Cáncer de próstata de inicio temprano. ¿Una nueva entidad?

Parra-Medina R, Ramírez-Clavijo S

Idioma: Español
Referencias bibliográficas: 65
Paginas: 1-13
Archivo PDF: 206.87 Kb.


RESUMEN

El cáncer de próstata (CP) es el segundo tipo de cáncer más frecuente y la quinta causa de muerte en hombres a nivel mundial. Se ha propuesto que el CP en jóvenes es una entidad diferente al de inicio tardío. No se ha establecido el punto de corte para definir CP de inicio temprano, pero con frecuencia se refiere al diagnóstico en pacientes menores de 50 años. Se ha observado que las características clínicas del CP de inicio temprano y de inicio tardía son similares, pero en pacientes jóvenes con alto riesgo de desarrollar la enfermedad puede ser más agresivo. También se ha descrito que los mecanismos moleculares de oncogénesis son diferentes entre jóvenes y viejos. El objetivo de la presente revisión es reunir evidencia de las características del CP de inicio temprano.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394– 424. doi: 10.3322/caac.21492

  2. Gandhi J, Afridi A, Vatsia S, Joshi G, Joshi G, Kaplan SA, et al. The molecular biology of prostate cancer: current understanding and clinical implications. Prostate Cancer Prostatic Dis. 2018;21(1):22–36. doi: 10.1038/s41391- 017-0023-8

  3. Kendal WS, Mai KT. Histological subtypes of prostatic cancer: a comparative survival study. Can J Urol. 2010;17(5):5355–9.

  4. Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J, et al. Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group. Int J Cancer. 2016;138(6):1388–400. doi: 10.1002/ijc.29894

  5. Bleyer A, Spreafico F, Barr R. Prostate cancer in young men: An emerging young adult and older adolescent challenge. Cancer. 2020;126(1):46– 57. doi: 10.1002/cncr.32498

  6. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324(17):1156–61. doi: 10.1056/ NEJM199104253241702

  7. Sánchez-Chapado M, Olmedilla G, Cabeza M, Donat E, Ruiz A. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate. 2003;54(3):238–47. doi: 10.1002/pros.10177

  8. Li J, German R, King J, Joseph D, Thompson T, Wu X-C, et al. Recent trends in prostate cancer testing and incidence among men under age of 50. Cancer Epidemiol. 2012;36(2):122–7. doi: 10.1016/j.canep.2011.10.014

  9. Howlader N,. Cancer Statistics Review, 1975-2014 - SEER Statistics. SEER. Available from: https:// seer.cancer.gov/archive/csr/1975_2014/

  10. Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: an important clinical entity. Nat Rev Urol. 2014;11(6):317–23. doi: 10.1038/ nrurol.2014.91

  11. Zheng Y, Lin SX, Wu S, Dahl DM, Blute ML, Zhong W-D, et al. Clinicopathological characteristics of localized prostate cancer in younger men aged ≤ 50 years treated with radical prostatectomy in the PSA era: A systematic review and meta-analysis. Cancer Medicine. 2020;9(18):6473–84. doi: 10.1002/cam4.3320

  12. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi: 10.3322/caac.21208

  13. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer. 2009;115(13):2863–71. doi: 10.1002/cncr.24324

  14. Tjaden HB, Culp DA, Flocks RH. Clinical adenocarcinoma of the prostate in patients under 50 years of age. J Urol. 1965;93:618–21. doi: 10.1016/s0022-5347(17)63840-0

  15. Wilson JM, Kemp IW, Stein GJ. Cancer of the prostate. Do younger men have a poorer survival rate? Br J Urol. 1984;56(4):391–6. doi: 10.1111/j.1464-410x.1984.tb05828.x

  16. Huang K-C, Dolph M, Donnelly B, Bismar TA. ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer. Clin Transl Oncol. 2014;16(11):973–9. doi: 10.1007/s12094-014-1182-x

  17. Huang T-H, Kuo J-Y, Huang Y-H, Chung H-J, Huang WJS, Wu HHH, et al. Prostate cancer in young adults—Seventeen-year clinical experience of a single center. Journal of the Chinese Medical Association. 2017;80(1):39– 43. doi: 10.1016/j.jcma.2016.10.004

  18. Grönberg H, Damber JE, Jonsson H, Lenner P. Patient age as a prognostic factor in prostate cancer. J Urol. 1994;152(3):892–5. doi: 10.1016/ s0022-5347(17)32601-0

  19. Becker A, Tennstedt P, Hansen J, Trinh Q-D, Kluth L, Atassi N, et al. Functional and oncological outcomes of patients aged <50 years treated with radical prostatectomy for localised prostate cancer in a European population. BJU Int. 2014;114(1):38–45. doi: 10.1111/bju.12407

  20. Parker PM, Rice KR, Sterbis JR, Chen Y, Cullen J, McLeod DG, et al. Prostate cancer in men less than the age of 50: a comparison of race and outcomes. Urology. 2011;78(1):110–5. doi: 10.1016/j.urology.2010.12.046

  21. Freedland SJ, Presti JC, Kane CJ, Aronson WJ, Terris MK, Dorey F, et al. Do younger men have better biochemical outcomes after radical prostatectomy? Urology. 2004;63(3):518–22. doi: 10.1016/j.urology.2003.10.045

  22. Shih H-J, Fang S-C, An L, Shao Y-HJ. Early-onset prostate cancer is associated with increased risks of disease progression and cancer-specific mortality. Prostate. 2021;81(2):118–26. doi: 10.1002/pros.24087

  23. Hussein S, Satturwar S, Van der Kwast T. Young-age prostate cancer. J Clin Pathol. 2015;68(7):511–5. doi: 10.1136/ jclinpath-2015-202993

  24. Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK. Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol Biomarkers Prev. 2014;23(8):1505–11. doi: 10.1158/1055-9965. EPI-13-1328

  25. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol. 2010;183(5):1792–6. doi: 10.1016/j.juro.2010.01.015

  26. Powell IJ, Banerjee M, Sakr W, Grignon D, Wood DP, Novallo M, et al. Should African- American men be tested for prostate carcinoma at an earlier age than white men? Cancer. 1999;85(2):472–7.

  27. Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur Urol. 2010;58(2):275–80. doi: 10.1016/j. eururo.2010.02.002

  28. Zeegers MPA, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer. 2003;97(8):1894–903. doi: 10.1002/ cncr.11262

  29. Bratt O, Damber J-E, Emanuelsson M, Grönberg H. Hereditary prostate cancer: clinical characteristics and survival. J Urol. 2002;167(6):2423–6.

  30. Kiciński M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS One. 2011;6(10):e27130. doi: 10.1371/ journal.pone.0027130

  31. Lange EM, Salinas CA, Zuhlke KA, Ray AM, Wang Y, Lu Y, et al. Early onset prostate cancer has a significant genetic component. Prostate. 2012;72(2):147–56. doi: 10.1002/pros.21414

  32. Carlson AS, Acevedo RI, Lim DM, Gulati R, Gawne A, Sokolova AO, et al. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. PLOS ONE. 2020;15(9):e0239686. doi: 10.1371/journal. pone.0239686

  33. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2011;12(1):68–78. doi: 10.1038/nrc3181

  34. Benson EK, Mungamuri SK, Attie O, Kracikova M, Sachidanandam R, Manfredi JJ, et al. p53- dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes. Oncogene. 2014;33(30):3959–69. doi: 10.1038/onc.2013.378

  35. Cavanagh H, Rogers KMA. The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Hered Cancer Clin Pract. 2015;13. doi: 10.1186/s13053-015-0038-x

  36. Singer CF. Homologous recombination deficiency: New biomarkers in innovative treatments. memo Mag Eur Med Oncol. 2020;13(4):357–8. doi: 10.1007/s12254-020- 00660-7

  37. Brechka H, Bhanvadia RR, VanOpstall C, Vander Griend DJ. HOXB13 mutations and binding partners in prostate development and cancer: Function, clinical significance, and future directions. Genes Dis. 2017;4(2):75–87. doi: 10.1016/j.gendis.2017.01.003

  38. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet. 2003;72(1):1–12. doi: 10.1086/345310

  39. Ferro M, Terracciano D, Buonerba C, Lucarelli G, Bottero D, Perdonà S, et al. The emerging role of obesity, diet and lipid metabolism in prostate cancer. Future Oncol. 2017;13(3):285– 93. doi: 10.2217/fon-2016-0217

  40. de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, et al. Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer. 2020 Aug;20(8):455–69. doi: 10.1038/ s41568-020-0267-9

  41. Thorstenson A, Garmo H, Adolfsson J, Bratt O. Cancer Specific Mortality in Men Diagnosed with Prostate Cancer before Age 50 Years: A Nationwide Population Based Study. J Urol. 2017;197(1):61–6. doi: 10.1016/j. juro.2016.06.080

  42. Rybak AP, Bristow RG, Kapoor A. Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. Oncotarget. 2015;6(4):1900– 19. doi: 10.18632/oncotarget.2953

  43. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606–19. doi: 10.1038/nrg1879

  44. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKTmTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol. 2008;8(4):393–412. doi: 10.1016/j.coph.2008.08.004

  45. Dan R, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–28. doi: 10.1016/j. cell.2015.05.001

  46. Hübner A, Mulholland DJ, Standen CL, Karasarides M, Cavanagh-Kyros J, Barrett T, et al. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A. 2012;109(30):12046–51. doi: 10.1073/ pnas.1209660109

  47. Liu S, Zhang Q, Chen C, Ge D, Qu Y, Chen R, et al. Hyperinsulinemia enhances interleukin- 17-induced inflammation to promote prostate cancer development in obese mice through inhibiting glycogen synthase kinase 3-mediated phosphorylationanddegradationofinterleukin-17 receptor. Oncotarget. 2016;7(12):13651–66. doi: 10.18632/oncotarget.7296

  48. Rodríguez-Berriguete G, Fraile B, Martínez- Onsurbe P, Olmedilla G, Paniagua R, Royuela M. MAP Kinases and Prostate Cancer. J Signal Transduct. 2012;2012:169170. doi: 10.1155/2012/169170

  49. Xu R, Hu J. The role of JNK in prostate cancer progression and therapeutic strategies. Biomed Pharmacother. 2020;121:109679. doi: 10.1016/j.biopha.2019.109679

  50. Ricote M, García-Tuñón I, Bethencourt F, Fraile B, Onsurbe P, Paniagua R, et al. The p38 transduction pathway in prostatic neoplasia. The Journal of Pathology. 2006;208(3):401–7. doi: 10.1002/path.1910

  51. Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015;163(4):1011–25. doi: 10.1016/j.cell.2015.10.025

  52. Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell. 2013;23(2):159–70. doi: 10.1016/j. ccr.2013.01.002

  53. Schaefer G, Mosquera J-M, Ramoner R, Park K, Romanel A, Steiner E, et al. Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer. Prostate Cancer Prostatic Dis. 2013;16(2):132–8. doi: 10.1038/pcan.2013.4

  54. Steurer S, Mayer PS, Adam M, Krohn A, Koop C, Ospina-Klinck D, et al. TMPRSS2- ERG fusions are strongly linked to young patient age in low-grade prostate cancer. Eur Urol. 2014;66(6):978–81. doi: 10.1016/j. eururo.2014.06.027

  55. Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, et al. Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. Cancer Cell. 2018;34(6):996-1011. e8. doi: 10.1016/j.ccell.2018.10.016

  56. Ding Y, Wu H, Warden C, Steele L, Liu X, Iterson M van, et al. Gene Expression Differences in Prostate Cancers between Young and Old Men. PLOS Genetics. 2016;12(12):e1006477. doi: 10.1371/journal.pgen.1006477

  57. Leongamornlert DA, Saunders EJ, Wakerell S, Whitmore I, Dadaev T, Cieza-Borrella C, et al. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. Eur Urol. 2019;76(3):329–37. doi: 10.1016/j. eururo.2019.01.050

  58. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15(6):321–33. doi: 10.1038/nrc3932

  59. Vanacore D, Boccellino M, Rossetti S, Cavaliere C, D’Aniello C, Di Franco R, et al. Micrornas in prostate cancer: an overview. Oncotarget. 2017;8(30):50240–51. doi: 10.18632/ oncotarget.16933

  60. Cannistraci A, Di Pace AL, De Maria R, Bonci D. MicroRNA as New Tools for Prostate Cancer Risk Assessment and Therapeutic Intervention: Results from Clinical Data Set and Patients’ Samples. BioMed Research International. 2014;2014:e146170. doi: 10.1155/2014/146170

  61. Luu HN, Lin H-Y, Sørensen KD, Ogunwobi OO, Kumar N, Chornokur G, et al. miRNAs associated with prostate cancer risk and progression. BMC Urol. 2017;17(1):18. doi: 10.1186/s12894-017-0206-6

  62. Valera VA, Parra-Medina R, Walter BA, Pinto P, Merino MJ. microRNA Expression Profiling in Young Prostate Cancer Patients. J Cancer. 2020;11(14):4106–14. doi: 10.7150/jca.37842

  63. Parra-Medina R, López-Kleine L, Ramírez- Clavijo S, Payán-Gómez C. Identification of candidate miRNAs in early-onset and late-onset prostate cancer by network analysis. Sci Rep. 2020;10(1):12345. doi: 10.1038/s41598-020- 69290-7

  64. Smith SC, Palanisamy N, Zuhlke KA, Johnson AM, Siddiqui J, Chinnaiyan AM, et al. HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. Am J Surg Pathol. 2014;38(5):615–26. doi: 10.1097/ PAS.0000000000000090

  65. Risbridger GP, Taylor RA, Clouston D, Sliwinski A, Thorne H, Hunter S, et al. Patientderived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur Urol. 2015;67(3):496–503. doi: 10.1016/j.eururo.2014.08.007




2020     |     www.medigraphic.com